Efficacy and safety of anlotinib in treatment of advanced non-small cell lung cancer: a meta analysis

Yang Li; He Jie; Ren Zhaoqiang; Li Xiaoyan; Xu Ke

doi:10.3760/j.issn.1673-4777.2020.04.016

Abstract：Objective To systematically evaluate the efficacy and safety of anlotinib in treatment of advanced non-small cell lung cancer(NSCLC). Methods Literatures of anlotinib treating NSCLC were searched in PubMed, Cochrane Library, EMbase, Web of Science, Wanfang Database, VIP Database and Chinese Journal Full-text Database from January 1st, 2014 to July 8th, 2019. The control group was treated with routine treatment. The experimental group was treated with anlotinib with or without other medication. Two researchers screened the literatures according to inclusion and exclusion criteria, extracted the data and evaluated the methodological quality. Revman 5.2 software was used for meta analysis. Results Five randomized controlled trials involving 695 NSCLC patients were included. Meta analysis showed that the disease control rate in the experimental group was better than that in the control group, with a significant difference [ relative risk =1. 68, 95％ confidence interval(CI):1. 08-2. 60, P=0. 02]; the progression-free survival and total survival in the experimental group were higher than those in the control group, with significant differences ( hazard ratio =0. 27, 0. 71; 95％CI:0. 22-0. 32, 0. 59-0. 85, both P<0. 05). Incidences of hypertension and diarrhea in the experimental group were significantly higher than those in the control group(both P <0. 001). There were no statistical differences in incidences of liver dysfunction, nausea and vomiting, grade Ⅲ-Ⅳ hemoptysis between groups( P=0. 27, 0. 05, 0.30). Conclusions Anlotinib is effective in treating advanced NSCLC, but it brings a high risk of hypertension and diarrhea. Other adverse reactions such as abnormal liver function, nausea and vomiting, gradeⅢ-Ⅳhemoptysis show equal incidences to the control group. The overall tolerance of patients is acceptable.